Novel Diagnostic and Therapeutic Options for Inflammatory Orbital Diseases

Dear Colleagues,

Despite the recent advances in the treatment of inflammatory orbital diseases, such as Graves’ orbitopathy (GO), idiopathic orbital inflammation, IgG4-ROD, etc., often remain challenging. It is therefore of utmost importance that patients receive an early diagnosis to avoid complications and rehabilitative surgery. New serum biomarker assays, and whole-transcriptome and metabolome analyses may lead to a faster diagnosis and more prognostic factors to enable a tailored, personalized treatment approach. Nevertheless, treatment mainly consists of steroids with limited targeted therapies available. While GO patients in the US already benefit from IGF-1-receptor inhibiting therapy, patients in Europe are still lacking specific therapy. For other orbital inflammatory diseases, there are worldwide no specific targeted therapy despite the high impact on the quality of life of afflicted patients. Thus, physicians need to rely on steroids and immunosuppressive agents, which are often only available as an ‘off-label’ option, due to missing randomized controlled trials.

Therefore, I would like to invite you to submit your latest research on novel diagnostic and therapeutic options for these orbitopathies to increase the security and speed of diagnosis, as well as the effectiveness of treatment.

Dr. Michael Oeverhaus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Graves’ orbitopathy
• thyroid eye disease
• thyroid-associated ophthalmopathy
• idiopathic orbital inflammation
• IgG4-related orbitopathy
• IgG4-ROD
• GO
• TED
• TAO
• IOI
• granulomatosis with polyangiitis
• GPA